Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19332413 | 0.91 | CTSL (0.36) | CTSLCTSK | |
| SCHEMBL782800 | 0.84 | CTSK (0.38) | CTSLCTSK | |
| SCHEMBL15268592 | 0.79 | CTSL (0.33) | CTSLCTSK | |
| SCHEMBL1973582 | 0.79 | USP2 (0.39) | CTSLCTSK | |
| SCHEMBL16427727 | 0.78 | CTSL (0.32) | CTSLCTSK | |
| SCHEMBL16427906 | 0.77 | CTSL (0.32) | CTSLCTSK | |
| SCHEMBL2780424 | 0.76 | CYP4F2 (0.36) | CTSLCTSK | |
| SCHEMBL4180966 | 0.73 | DGAT1 (0.32) | — | |
| SCHEMBL4214456 | 0.70 | DGAT1 (0.36) | — | |
| SCHEMBL4193423 | 0.70 | CYP4F2 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090047244-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS I | IDENIX PHARMACEUTICALS, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| WO-2009014730-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2009-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090047244-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS I | SERPINB1, SPINT2, PRSS1 | CTSL 24/4885CTSK 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.